Blue Shield of California parent seeks subscription model for GLP-1 drug coverage

Blue Shield of California parent seeks subscription model for GLP-1 drug coverage
GLP-1 Drug Subscription Model

Rising demand for GLP-1 medicines is pushing health insurers to look for new payment structures that better align cost with patient outcomes. In California, Blue Shield of California parent Ascendiun is proposing a subscription-style approach that could lower what patients pay while linking insurer spending to drug performance.

Highlights

  • Ascendiun CEO Paul Markovich proposed a subscription and bonus model for GLP-1 coverage, paying drugmakers monthly plus outcome-based bonuses.
  • The model aims to contain GLP-1 drug spending growth by linking payments to patient results like blood sugar and weight reduction, rather than pure coverage restrictions.
  • The approach seeks to lower members' out-of-pocket costs and pushes drugmakers to demonstrate broader clinical benefits to maintain bonus eligibility.

Proposed payment model for GLP-1 access

As reported by Bloomberg, Ascendiun Chief Executive Officer Paul Markovich said the insurer wants to shift GLP-1 coverage toward a subscription and bonus model discussed during an interview at Bloomberg's New York offices.

Under the approach, the insurer would pay drugmakers a monthly fee so all of its members can access the medicines when needed. It would then pay additional amounts if patients reach positive outcomes such as lower blood sugar or weight reduction.

Potential impact on drug spending

The proposal reflects growing pressure on insurers to manage the high cost of GLP-1 drugs as use expands for diabetes and weight loss treatment. Tying reimbursement more directly to results could give payers a way to limit waste while preserving broader access for members.

For patients, the model is aimed at reducing out-of-pocket spending by changing how the insurer purchases coverage rather than restricting eligibility alone. For drugmakers, it would place more emphasis on demonstrating measurable clinical benefits across a larger covered population.

We have previously noted Fitch downgrade at Regional West Health Services amid persistent losses and very weak liquidity.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.